|
Merkel cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The CT antigens SP-17, IMP-3, and TMEFF1 were selected using transcriptome profiling to identify CT antigens expressed in MCC tumors.
|
31218705 |
2019 |
|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Insulin-like growth factor 2 mRNA-binding protein 3 (IMP3) and vascular endothelial growth factor-A (VEGF-A) may play important roles in the process of tumor progression and tumor angiogenesis.
|
31611984 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of IMP-3 expression pattern in esophageal squamous cell carcinoma.
|
31656650 |
2019 |
|
Tumor Angiogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Insulin-like growth factor 2 mRNA-binding protein 3 (IMP3) and vascular endothelial growth factor-A (VEGF-A) may play important roles in the process of tumor progression and tumor angiogenesis.
|
31611984 |
2019 |
|
oligodendroglioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report that the BCAN, CSPG4, IGF2BP3, PTPRZ1 and TNC proteins are significantly over-expressed at the mRNA (n = 159) and protein (n = 36) levels in grade II/III glioma patients as compared to non-tumor samples (IGF2BP3 being absent from oligodendroglioma).
|
29308320 |
2018 |
|
Adult Oligodendroglioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report that the BCAN, CSPG4, IGF2BP3, PTPRZ1 and TNC proteins are significantly over-expressed at the mRNA (n = 159) and protein (n = 36) levels in grade II/III glioma patients as compared to non-tumor samples (IGF2BP3 being absent from oligodendroglioma).
|
29308320 |
2018 |
|
Childhood Oligodendroglioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report that the BCAN, CSPG4, IGF2BP3, PTPRZ1 and TNC proteins are significantly over-expressed at the mRNA (n = 159) and protein (n = 36) levels in grade II/III glioma patients as compared to non-tumor samples (IGF2BP3 being absent from oligodendroglioma).
|
29308320 |
2018 |
|
Well Differentiated Oligodendroglioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report that the BCAN, CSPG4, IGF2BP3, PTPRZ1 and TNC proteins are significantly over-expressed at the mRNA (n = 159) and protein (n = 36) levels in grade II/III glioma patients as compared to non-tumor samples (IGF2BP3 being absent from oligodendroglioma).
|
29308320 |
2018 |
|
Localized Ewing Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigated the significance of the RNA-binding protein IGF2BP3 in the regulation of Ewing sarcoma aggressiveness.<b>Experimental Design:</b> Explorative study was performed in 14 patients with localized Ewing sarcoma using RNA sequencing.
|
29703820 |
2018 |
|
Malignant neoplasm of thyroid
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<i>THADA</i> fusions and IGF2BP3 overexpression are found in ∼5% of thyroid cancers that lack any other driver mutations.
|
28193878 |
2017 |
|
Dwarfism
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Let-7b has higher expression in the skeletal muscle of dwarf chicken than in normal chicken, and the expression of insulin-like growth factor 2 mRNA binding protein 3 (<i>IGF2BP3</i>), which is a translational activator of IGF2, showed opposite expression trend to let-7b.
|
28736533 |
2017 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
IGF2 mRNA-binding protein 3 (IMP3), a GBM upregulated RNA binding protein, promotes glioma cell migration.
|
28465487 |
2017 |
|
Thyroid Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>THADA</i> fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer.
|
28193878 |
2017 |
|
Thyroid Gland Follicular Adenoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using whole-transcriptome and whole-genome analyses, we identified a recurrent fusion between the thyroid adenoma-associated (<i>THADA</i>) gene on chromosome 2 and the <i>LOC389473</i> gene on chromosome 7 located 12 kb upstream of the <i>IGF2BP3</i> gene.
|
28193878 |
2017 |
|
Thyroid carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<i>THADA</i> fusions and IGF2BP3 overexpression are found in ∼5% of thyroid cancers that lack any other driver mutations.
|
28193878 |
2017 |
|
Esophageal High Grade Intraepithelial Neoplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results suggested that IGF2BP3 may be a supplementary tissue marker for preoperative diagnosis of HGIN.
|
28814885 |
2017 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
IGF2 mRNA-binding protein 3 (IMP3), a GBM upregulated RNA binding protein, promotes glioma cell migration.
|
28465487 |
2017 |
|
Resistance to Insulin-Like Growth Factor I
|
0.010 |
Biomarker
|
disease |
BEFREE |
<i>THADA</i> fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer.
|
28193878 |
2017 |
|
Childhood B Acute Lymphoblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, our data suggest that IGF2BP3-mediated targeting of oncogenic transcripts may represent a critical pathogenetic mechanism in MLL-rearranged B-ALL and support IGF2BP3 and its cognate RNA-binding partners as potential therapeutic targets in this disease.
|
26974154 |
2016 |
|
Adult B Acute Lymphoblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, our data suggest that IGF2BP3-mediated targeting of oncogenic transcripts may represent a critical pathogenetic mechanism in MLL-rearranged B-ALL and support IGF2BP3 and its cognate RNA-binding partners as potential therapeutic targets in this disease.
|
26974154 |
2016 |
|
Pre B-cell acute lymphoblastic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, our data suggest that IGF2BP3-mediated targeting of oncogenic transcripts may represent a critical pathogenetic mechanism in MLL-rearranged B-ALL and support IGF2BP3 and its cognate RNA-binding partners as potential therapeutic targets in this disease.
|
26974154 |
2016 |
|
Epithelioid mesothelioma, malignant
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the immunohistochemical analysis, Noxa showed sensitivity of 69.0%, specificity of 93.6% and positive predictive value of 93.0% as a positive marker of EM in distinguishing it from RMH, and these values were almost similar to IMP-3.
|
26735863 |
2016 |
|
Precursor B-cell lymphoblastic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, our data suggest that IGF2BP3-mediated targeting of oncogenic transcripts may represent a critical pathogenetic mechanism in MLL-rearranged B-ALL and support IGF2BP3 and its cognate RNA-binding partners as potential therapeutic targets in this disease.
|
26974154 |
2016 |
|
Triple Negative Breast Neoplasms
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression analysis of the panel of TNBC cell lines indicates that the expression levels of IGF2BP3 can be used as a potential predictor for sensitivity to the PI3K/IGF1R inhibitor combination.
|
27196766 |
2016 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression analysis of the panel of TNBC cell lines indicates that the expression levels of IGF2BP3 can be used as a potential predictor for sensitivity to the PI3K/IGF1R inhibitor combination.
|
27196766 |
2016 |